Navigation Links
FDA Approves XYZAL(R) For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria
Date:8/24/2009

ATLANTA and BRIDGEWATER, N.J., Aug. 24 /PRNewswire/ -- UCB and sanofi-aventis U.S. announced today that the U.S. Food and Drug Administration (FDA) has approved XYZAL(R) (levocetirizine dihydrochloride) for children age six months and older for the relief of symptoms of perennial allergic rhinitis (indoor allergies) and chronic idiopathic urticaria (chronic hives) and for children age two years and older for symptoms of seasonal allergic rhinitis (outdoor allergies). Until now, XYZAL(R), a once-daily prescription antihistamine in both tablet and liquid formulations, has been used to treat symptoms of indoor and outdoor nasal allergies, as well as chronic idiopathic urticaria in patients age six years and older.

"There are options for treating nasal allergies in young children, one of which is XYZAL(R). The availability of a liquid treatment with the established safety and efficacy of XYZAL(R) provides caregivers a new treatment option that can help relieve nasal allergy symptoms in young patients once diagnosed by a physician," said Michael Blaiss, M.D., clinical professor of pediatrics and medicine at the University of Tennessee Health Science Center; past president of the American College of Allergy, Asthma, and Immunology (ACAAI) and co-editor of the Atlas of Allergic Diseases.

Nasal allergies are currently the most common chronic condition found in children, with allergic rhinitis believed to affect as many as 40 percent of U.S. children. Recognizing the symptoms and increased hereditary risk are key elements to ensuring early diagnosis and proper management. A child with one parent living with allergies has a 48 percent chance of developing allergies, while a child with two parents living with allergies has a 70 percent chance of developing allergies.

XYZAL(R) tablets received FDA approval on May 25, 2007 and XYZAL(R) oral solution received FDA
'/>"/>

SOURCE UCB; sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Health Canada Approves Abbotts XIENCE V(R) Drug Eluting Stent
2. First 5 California Approves $81.4 Million Contribution to Help Restore Healthy Families Programs Viability
3. Video: FDA Approves EMBEDA(TM) For Management of Moderate to Severe Chronic Pain
4. FDA Approves New 3000 IU Vial Size for Kogenate(R) FS, antihemophilic factor (recombinant)
5. FDA Approves LIVALO(R) for Primary Hypercholesterolemia and Combined Dyslipidemia
6. FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
7. House Committee Approves Amendment Eliminating Cost-Sharing for Medicaid Preventive Services
8. FDA Approves TYVASO (Treprostinil) Inhalation Solution for the Treatment of Pulmonary Arterial Hypertension
9. FDA Approves Sculptra(R)Aesthetic, a Facial Injectable for Correction of Nasolabial Folds and Other Facial Wrinkles
10. Kaiser Permanente Approves $11 Million in Community Benefit Grants
11. FDA Approves Expanded Use of Lillys FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... 27, 2015 , ... About 10 percent of mothers experienced ... Coast, killing more than 1,800 people, displacing hundreds of thousands and causing widespread ... study. , While most people don’t develop persistent depression after a major disaster ...
(Date:8/27/2015)... ... August 27, 2015 , ... StayWell, a ... Patient Education content is ICD-10 ready and available to all clients. All Krames ... code sets, which are more targeted and return a more comprehensive data set ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... In addition ... Alvernia University now offers a third doctoral program at its main campus in Reading: ... a terminal degree program designed to prepare advanced practice nurses for the highest level ...
(Date:8/27/2015)... London, UK (PRWEB) , ... ... ... Ltd and Black Swan Analysis signed a partnership agreement for quality market ... sell research reports elaborated by Black Swan Analysis. , Commenting on the ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... Sunbelt® Bakery, ... high fructose corn syrup, is changing the expectation of how protein bars should taste ... indulgent taste unlike any other protein bar on the market today. , The ...
Breaking Medicine News(10 mins):Health News:About 10 Percent of Mothers Experienced Depression Two Years After Hurricane Katrina, New Study Shows 2Health News:StayWell announces all health content is ICD-10 ready 2Health News:StayWell announces all health content is ICD-10 ready 3Health News:Alvernia University Now Offering Three Doctoral Degree Programs 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 3Health News:Sunbelt® Bakery Changes the Expectations of How Protein Bars Should Taste with the Introduction of Its New Protein Delights 2Health News:Sunbelt® Bakery Changes the Expectations of How Protein Bars Should Taste with the Introduction of Its New Protein Delights 3
... reduces the risk of heart disease. But almost everyone feels ... recent study shows that skinny people are also prone to ... factors in the genesis of various heart ailments. ,Dr. ... who headed the study, says that heart disease does not ...
... is playing havoc with the economies of,developed countries like ... of vaccinating the animals for the past three decades. ... regular basis is the best,means of preventing the spread ... joint,director of the Bangalore-based Indian Veterinary Research Institute (under,ICAR), ...
... research backed by the British government says that smoking will ... to come, surpassing the threat of even HIV. The British ... smoking will kill more people than any other disease in ... of Development Studies in Sussex, United Kingdom, says smoking and ...
... States of America has zeroed in on the culprit behind ... isolated which is said to be the cause for girls ... most widely held explanation for this is growing childhood obesity, ... were keen on the role of estrogen, a female hormone, ...
... are paranoid about heart disease. One survey said that of ... heart disease. Whenever people get to read something on heart ... worrying at times over trivial problems based on the assumption ... conducted in Austria says that chronic infections can predispose to ...
... A study conducted by Dr. Michael Brent, an associate ... St. Louis, gives us an insight into the way ... age.,These findings were presented at the annual meeting of ... San Francisco.,For years the ability of children to pick ...
Cached Medicine News:Health News:India takes on foot-and-mouth disease by vaccinating animals 2
(Date:8/27/2015)... FRANCISCO, Calif. , Aug. 27, 2015 /PRNewswire/ ... therapeutics for the treatment of cancer, today announced ... member of the company,s Board of Directors, has ... led immuno-oncology at Eli Lilly and AstraZeneca, and ... first FDA approved checkpoint inhibitor, at Bristol-Myers Squibb ...
(Date:8/27/2015)... and MENLO PARK, Calif. , ... (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company ... therapies, today announced that it will release its year-end ... 2015 on Friday, September 4, 2015. ... call and live webcast for investors, analysts and other ...
(Date:8/27/2015)... , Aug. 27, 2015  SciClone Pharmaceuticals, Inc. (NASDAQ: ... PhD, Chief Executive Officer, will present a corporate overview and ... in New York City . , ... at 11:30 am ET at the Millennium Broadway Hotel. ... 3:00 pm ET at the St. Regis Hotel. ...
Breaking Medicine Technology:Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 2Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 3DelMar Pharmaceuticals to Announce Fiscal 2015 Year-End Financial Results on September 4, 2015 2DelMar Pharmaceuticals to Announce Fiscal 2015 Year-End Financial Results on September 4, 2015 3SciClone To Present At Two Investor Conferences On September 10, 2015 2
... , NANJING , China ... SCR ), a leading manufacturer and supplier of ... (also known as Endu) in China , announced today ... conference in Beijing ,dedicated to this study. The New ...
... March 18 Jeffrey B. Kindler , ... chairman of the Pharmaceutical Research and Manufacturers of America ... elected were sanofi-aventis Chief Executive Officer Christopher Viehbacher ... and John C. Lechleiter , Ph.D., Chairman, President ...
Cached Medicine Technology:Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study 2Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study 3Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study 4Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study 5Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 2Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 3Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 4Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 5Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 6Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 7Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 8
New - Color Coded Berman Airways. A simple idea makes size identification easier for you., ,Premium upgrade without a premium price. Color Coded Berman airways are latex-free., ,Plastic. Single use...
Plastic. Economical. Single use. Non-Sterile....
... Portex® Blue Line® uncuffed endotracheal ... or Murphy styles, in standard ... Line® adult and pediatric uncuffed ... implant-tested polyvinyl chloride with a ...
... Portex® Blue Line® uncuffed endotracheal ... or Murphy styles, in standard ... Line® adult and pediatric uncuffed ... implant-tested polyvinyl chloride with a ...
Medicine Products: